Quantum BioPharma is trading 8.38% up at $3.75 after the FDA approved its Investigational New Drug application for Lucid-MS on August 10, 2026, allowing the multiple sclerosis treatment to advance into Phase 2 development.

  • Trial start-up activities, including site selection, are underway
  • Patient enrollment and drug administration are expected to begin quickly
  • Broader market futures are mixed, limiting macro support